能倍乐治疗慢性阻塞性肺病的效果

Respimat is suitable for the maintenance treatment of chronic obstructive pulmonary disease, including chronic bronchitis and emphysema, the maintenance treatment of dyspnea and the prevention of acute exacerbations; the therapeutic effect of treating chronic obstructive pulmonary disease:

Purpose: To study the clinical effect of using Respimat combined with spacer inhaled drugs in elderly patients with chronic obstructive pulmonary disease (COPD).

Methods: 77 patients with chronic obstructive pulmonary disease who were treated in the hospital were collected and randomly divided into two groups. The experimental group (n=40) was treated with Respimat and spacer, and the control group (n=37) was treated with Respimat device inhalation. The inhaled drugs are all tiotropium bromide. The general characteristics, lung function indicators, blood gas analysis indicators, clinical efficacy, etc. of the two groups were detected and compared.

Results The FEV1, FVC and FEV1/FVC of the two groups of patients increased after treatment, and the differences were statistically significant (P<0.05). Comparing the two groups, the differences in FEV1, FVC and FEV1/FVC of the experimental group before and after treatment were greater than those of the control group, and the differences were statistically significant (P<0.05).

There was no significant difference in pH, PaO2 and PaCO2 between the two groups of patients before treatment (P0.05), and there was no significant difference in pH after treatment (P0.05). After treatment, PaO2 increased and PaCO2 decreased in both groups, and the differences were statistically significant (P<0.05). Comparing the two groups, after treatment, the PaO2 of the experimental group was greater than that of the control group, and the PaCO2 was less than that of the control group, and the difference was statistically significant (P0.05). The total effective rate of clinical treatment effect in the experimental group was significantly greater than that in the control group, and the difference was statistically significant (P0.05).

Conclusion: In patients with chronic obstructive pulmonary disease, inhaling tiotropium bromide with a spacer can better improve lung function indicators and blood gas indicators, and obtain better clinical effect analysis. It suggests that the combined use of spacers in the treatment of COPD can achieve better clinical effects and provide certain guidance for clinical treatment.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician. 

Recommended related articles: